• 1

    Jemal A, Siegel R, Ward E et al.. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:3742.

    • Search Google Scholar
    • Export Citation
  • 3

    DeVita VT Jr, Hellman S, Rosenberg SA et al.. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.

    • Search Google Scholar
    • Export Citation
  • 4

    Choyke PL. Hereditary renal cancers. Radiology 2003;226:3346.

  • 5

    Ries LAG, Melbert D, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.

    • Search Google Scholar
    • Export Citation
  • 6

    Hricak H, Demas BE, Williams RD et al.. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709715.

    • Search Google Scholar
    • Export Citation
  • 7

    Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diag Imaging 1991;32:69118.

  • 8

    Dechet CB, Zincke H, Sebo TJ et al.. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003;169:7174.

    • Search Google Scholar
    • Export Citation
  • 9

    Hollingsworth JM, Miller DC, Dunn RL et al.. Surgical management of low-stage renal cell carcinoma: technology does not supersede biology. Urology 2006;67:11751180.

    • Search Google Scholar
    • Export Citation
  • 10

    Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment or renal cell carcinoma. Curr Urol Rep 2006;7:3138.

  • 11

    Leibovich BC, Blute ML, Cheville JC et al.. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;17:10661070.

    • Search Google Scholar
    • Export Citation
  • 12

    Lui KW, Gervais DA, Mueller PR. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. Chang Gung Med J 2004;27:618623.

    • Search Google Scholar
    • Export Citation
  • 13

    Lewin JS, Nour SG, Connell CF et al.. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 2004;232:835845.

    • Search Google Scholar
    • Export Citation
  • 14

    Gill IS, Remer EM, Hasan WA et al.. Renal cryoablation: outcome at 3 years. J Urol 2005;173:19031907.

  • 15

    Rouviere O, Bouvier R, Negrier S et al.. Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up. Nat Clin Pract Oncol 2006;3:200213.

    • Search Google Scholar
    • Export Citation
  • 16

    Messing EM, Manola J, Wilding G et al.. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:12141222.

    • Search Google Scholar
    • Export Citation
  • 17

    Clark JI, Atkins MB, Urba WJ et al.. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J Clin Oncol 2003;21:31333140.

    • Search Google Scholar
    • Export Citation
  • 18

    Trump DL, Elson P, Propert K et al.. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 253.

    • Search Google Scholar
    • Export Citation
  • 19

    Kavolius JP, Mastorakos DP, Pavlovich C et al.. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:22612266.

  • 20

    Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8:340342.

  • 21

    Flanigan RC, Mickisch G, Sylvester R et al.. Cytoreductive nephrectomy in patients with metastatic renal cancer. A combined analysis. J Urol 2004;171:10711076.

    • Search Google Scholar
    • Export Citation
  • 22

    Flanigan RC, Salmon SE, Blumenstein BA et al.. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:16551659.

    • Search Google Scholar
    • Export Citation
  • 23

    Mickisch GH, Garin A, van Poppel H et al.. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966970.

    • Search Google Scholar
    • Export Citation
  • 24

    Negrier S, Escudier B, Lasset C et al.. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:12731278.

    • Search Google Scholar
    • Export Citation
  • 25

    Yang JC, Sherry RM, Steinberg SM et al.. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:31273132.

    • Search Google Scholar
    • Export Citation
  • 26

    Dutcher JP, Fisher RI, Weiss G et al.. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157162.

    • Search Google Scholar
    • Export Citation
  • 27

    Motzer RJ, Basik J, Murphy BA et al.. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289296.

    • Search Google Scholar
    • Export Citation
  • 28

    Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884896.

  • 29

    Faivre S, Delbaldo C, Vera K et al.. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:2535.

    • Search Google Scholar
    • Export Citation
  • 30

    Motzer RJ, Hutson TE, Tomczak P et al.. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 31

    Figlin RA, Hutson TE, Tomczak MD et al.. Overall survival with sunitinib versus interferon (IFN-)alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 5024.

    • Search Google Scholar
    • Export Citation
  • 32

    Wilhelm SM, Carter C, Tang L et al.. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:70997109.

    • Search Google Scholar
    • Export Citation
  • 33

    Moore M, Hirte HW, Siu L et al.. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:16881694.

    • Search Google Scholar
    • Export Citation
  • 34

    Strumberg D, Richly H, Hilger RA et al.. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965972.

    • Search Google Scholar
    • Export Citation
  • 35

    Awada A, Hendlisz A, Gil T et al.. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:18551861.

    • Search Google Scholar
    • Export Citation
  • 36

    Clark JW, Eder JP, Ryan D et al.. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:54725480.

    • Search Google Scholar
    • Export Citation
  • 37

    Szczylik T, Demkow M, Staehler F et al.. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007;25(18S):5025.

    • Search Google Scholar
    • Export Citation
  • 38

    Gibbons JJ, Discafani C, Peterson R. The effect of CCI-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract]. Proc Am Assoc Cancer Res 1999;40:Abstract 301.

    • Search Google Scholar
    • Export Citation
  • 39

    Hudes G, Carducci M, Tomczak P et al.. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

  • 40

    Yang JC, Haworth L, Sherry RM et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427434.

    • Search Google Scholar
    • Export Citation
  • 41

    Escudier B, Pluzanska A, Koralewski P et al.. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:21032111.

    • Search Google Scholar
    • Export Citation
  • 42

    Rini BI, Halabi S, Rosenberg JE et al.. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:54225428.

    • Search Google Scholar
    • Export Citation
  • 43

    Wenzel C, Locker G, Schmidinger M et al.. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. Am J Kidney 2002;39:4854.

    • Search Google Scholar
    • Export Citation
  • 44

    Oevermann K, Buer L, Hoffmann R et al.. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83:583587.

  • 45

    Stadler WM, Halabi S, Ernstoff MS et al.. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of Cancer and Leukemia Group B #90008 [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 4515.

    • Search Google Scholar
    • Export Citation
  • 46

    Nanus DM, Garino A, Milowsky MI et al.. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:15451551.

    • Search Google Scholar
    • Export Citation
  • 47

    Motzer RJ, Escudier B, Oudard S et al.. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449456.

    • Search Google Scholar
    • Export Citation
  • 48

    Ratain MJ, Eisen T, Stadler WM et al.. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:25052512.

    • Search Google Scholar
    • Export Citation
  • 49

    Escudier B, Eisen T, Stadler WM et al.. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125134.

  • 50

    Eisen T, Bukowski RM, Staehler M et al.. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1): Abstract 4524.

    • Search Google Scholar
    • Export Citation
  • 51

    Bukowski RM, Eisen T, Szczylik C et al.. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023.

    • Search Google Scholar
    • Export Citation
  • 52

    Motzer RJ, Rini BI, Bukowski RM et al.. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:25162524.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1616 697 93
PDF Downloads 1291 617 72
EPUB Downloads 0 0 0